Mobile

A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon α-2a and ribavirin in people with hepatitis C virus who did not respond to tr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005393-32

A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon α-2a and ribavirin in people with hepatitis C virus who did not respond to treatment in a previous AbbVie or Abbott combination study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the safety and antiviral efficacy, defined as the percentage of subjects with sustained virologic response 12 weeks post-dosing (SVR12; HCV RNA < LLOQ 12 weeks after the last dose of study drug).

Critère d'inclusion

  • Chronic Hepatitis C Infection

Liens